Table 4.
Subgroup analysis at follow-up
| TroponinT | < 14 ng/l (n = 18) | > 14 ng/l (n = 19) | p value |
|---|---|---|---|
| LVEF % (median/IQR) | 55.5 (54.3 to 59.8) | 57.0 (52.3 to 61.3) | 0.552 |
| GLS % (median/IQR) | − 19.1 (− 20.7 to − 18.1) | − 19.7 (− 21.4 to − 17.4) | 0.593 |
| TAPSE mm (median/IQR) | 21.0 (20.0 to 23.8) | 23.0 (19.5 to 26.0) | 0.621 |
| RV S’ cm/s (median/IQR) | 12.0 (10.3 to 15.5) | 14 (11.5 to 15.5) | 0.525 |
| NT-proBNP | < 300 pg/mL (n = 18) | > 300 pg/mL (n = 20) | |
| LVEF % (median/IQR) | 57.0 (54.0 to 59.5) | 55.5 (52.3 to 60.4) | 0.557 |
| GLS % (median/IQR) | − 19.7 (− 21.4 to − 18.2) | − 19.1 (− 20.7 to − 17.0) | 0.429 |
| TAPSE mm (median/IQR) | 21.0 (19.5 to 26.0) | 22.5 (20.0 to 23.8) | 0.368 |
| RV S’ cm/s (median/IQR) | 12.0 (11.0 to 15.0) | 13.0 (11.0 to 16.0) | 0.886 |
| Treatment | No ICU admission (n = 26) | ICU admission (n = 14) | |
| LVEF % (median/IQR) | 56.0 (53.5 to 60.3) | 55.5 (52.5 to 60.3) | 0.659 |
| GLS % (median/IQR) | − 19.1 (− 21.1 to − 17.3) | − 19.7 (− 20.5 to− 18.3) | 0.981 |
| TAPSE mm (median/IQR) | 21.0 ( 20.0 to 24.5) | 23 (18.8 to 26.0) | 0.871 |
| RV S’ cm/s (median/IQR) | 12.0 (11.0 to 15.5) | 13.5 (10.5 to 15.8) | 0.783 |
| Complication during hospitalization | No pulmonary embolism (n = 33) | Pulmonary embolism (n = 7) | |
| LVEF % (median/IQR) | 58.0 (54.0 to 60.3) | 58.0 (55.0 to 61.0) | 0.775 |
| GLS % (median/IQR) | − 19.1 (− 21.2 to− 18.0) | − 19.4 (− 20.1 to − 18.6) | 0.921 |
| TAPSE mm (median/IQR) | 22.0 (20.0 to 25.0) | 22.0 (20.0 to 24.0) | 0.941 |
| RV S’ cm/s (median/IQR) | 13.0 (11.0 to 15.0) | 13.0 (11.0 to 15.0) | 0.805 |
| Symptoms (dyspnea/chest pain/fatigue/peripheral edema after COVID-19) | No symptoms (n = 26) | Symptoms (n = 14) | |
| LVEF % (median/IQR) | 56.8 (54.0 to 60.1) | 59.3 (56.5 to 61.9) | 0.151 |
| GLS % (median/IQR) | − 19.1 (− 20.4 to − 18.3) | − 19.1 (− 21.9 to − 17.3) | 0.658 |
| TAPSE mm (median/IQR) | 22.5 (20.0 to 25.3) | 21.0 (19.5 to 25.0) | 0.765 |
| RV S’ cm/s (median/IQR) | 13.0 (11.0 to 15.0) | 14.0 (10.5 to 15.0) | 0.938 |
All values were tested with a Mann–Whitney U test
GLS global longitudinal strain, LV left ventricular, LVEF left ventricular ejection fraction, RV S’ right ventricular systolic excursion velocity, TAPSE tricuspid annular plane systolic excursion